AstraZeneca's Fasenra Fails in Trial of Severe Lung Disease

(Bloomberg) -- AstraZeneca Plc’s Fasenra failed to meet its goal in a late-stage trial of patients with chronic obstructive pulmonary disease, a blow for the company as it tries to expand the marke...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.